INTRODUCTION
Breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancerrelated death in women. The American Cancer Society estimates that 249, 260 Americans will be diagnosed with invasive breast cancer and 40, 890 will die of the disease in the United States in 2016. 1 The treatment of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The need for and selection of various local or systemic therapies are based on several prognostic and predictive factors. These factors include tumor histology, clinical and pathologic characteristics of the primary tumor, ALN status, tumor hormone receptor (ER & PR) content, tumor HER2 status. Adjuvant endocrine therapy is an integral component of care for endocrine-dependent breast cancer (EDBC). The goal of this type of therapy is to counteract the production and the action of oestrogens. 2 The ovaries of premenopausal women who received chemotherapy typically have normal to mildly decreased numbers of primordial follicles and a greater decrease in the numbers of maturing follicles, indicating a greater effect on follicular development than on oocytes. Consistent with these histologic findings are the clinical observations that many women are amenorrhoeic during chemotherapy, often with high serum gonadotrophin concentrations, but that menstrual function and fertility often return several months to years after the cessation of therapy. 3 Chemotherapy-induced amenorrhea is a wellrecognized side effect of cytotoxic chemotherapy. These drugs appear to have a greater effect on follicular development than on oocytes, with variable degrees of subsequent ovarian dysfunction. Some women develop complete follicular depletion and permanent ovarian failure during chemotherapy, while others may become amenorrhoeic during therapy, but then have subsequent return of ovarian function, menstrual cycles, and fertility, months to years after the cessation of therapy. There are wellrecognized risk factors for chemotherapy-induced Authorship: All authors have a substantial contributions to the article. Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.
Clinical Oncology amenorrhea or ovarian failure, such as age, chemotherapy regimen, subsequent use of endocrine therapy and genetics. 4
PATIENT AND METHODS
This retrospective study included all patients with breast cancer with at least a minimum follow up of six months after last cycle of chemotherapy either clinically or by E 2 and FSH. Number of patients enrolled in this study is 97 patients from January 2009 to December 2015. 
ETHICAL APPROVAL:
Informed consents were obtained from all participants during their follow up at clinic, and data confidentiality was maintained throughout the study and any resulting publication anonymously.
STATISTICAL METHODS:
Amenorrhea defined as absence of menstruation in a woman of reproductive age for more than 6 months either clinically or by E 2 20<, FSH >20. Data presented as mean and standard deviation or median and range as appropriate. Categorical data will be presented as frequency and percentage. Relation between categorical data done using or appropriate statistical test. For quantitative data comparison between two groups done using either parametric or non parametric t-test. P-value less than 0.05 will be considered significant.
RESULTS

Patient's characteristics:
The mean age of all patients was 41.3 years ranges between (28-54) years. Out of these patients, 93 (95.9%) were married while 4 patients (4.1%) were single. Seventy-seven patients (79.4%) gave history of regular menses while 16 (21.6%) patients had history for irregular menstruation. Table ( 
DISCUSSION
Breast cancer is the commonest malignancy affecting females worldwide, it is estimated to be the fifth cause of death in cancer related mortalities. Breast cancer is a systemic disease, meaning that it require systemic treatment as main line of therapy, chemotherapy is the key player in adjuvant treatment of breast cancer patients, may regimens has been discussed in literature proving that Anthracycline based chemotherapy lead to best prognosis, in addition to paclitaxel it has improved the OS and DFS in patients with advanced stages. 5 Chemotherapy induced amenorrhea and fertility preservation has been a critical point of discussion since 6, 7 found that 41% of breast cancer survivors experienced amenorrhea during treatment, while Melanie and colleagues confirmed that 31% of their sample had amenorrhea during chemotherapy treatment, in our study 33% had chemotherapy induced amenorrhea.
In the current study, age was found to be statistically correlated to chemotherapy induced amenorrhea as patients with older ages are more borne for permanent amenorrhea and ovarian failure while younger ages were more borne to transient amenorrhea with p value 0.0001, any authors have confirmed same results. 8, 9 It is believed that regularity of menses is correlated with induction of amenorrhea post chemotherapy as detailed by 10 patients who had a Hodgkin's disease with irregular menses experienced longer amenorrhea period than those with regular one, in our study patients with regular menses had lower incidence of chemotherapy induced amenorrhea with p value 0.001 when compared to those with irregular menses. 10 Our study was the first to find a statistically significant correlation between chronic disease as DM and CIA with p value 0.013 when compared to patients who didn't suffer from DM, nonetheless we discovered that patients who had CBS had lower rates of CIA, this may be due to younger women tend to have conservative surgeries to maintain the cosmetic contour of the breast while older women usually go for MRM to avoid adjuvant chemotherapy and postoperative radiation p value 0.001.
Knowing that in our sample patients who had HER 2 negative IHC stain had significantly lower rates of CIA when compared to those HER 2 positive stain with p value 0.001. In the current study, we have found a correlation between DFS and CIA which imply that patients who had CIA had better survival than those with CIA however this difference was not significant, p value 0.129, Overall survival show no difference based on CIA p value 0.319.
Many limitations have been faced in our study, being a retrospective study, it had missed data and incomplete follow up records, larger prospective studies are needed to confirm prognosis of CIA on patient's survival, as well as investigation of other protocols and malignancies.
CONCLUSION
CIA is a main concern for females treated with breast cancer, it was found correlated to age, tumor stage, tumor biology and type of surgery. More prospective studies are needed to confirm correlation between CIA and prognosis of breast cancer, nonetheless other treatment regimens and malignancies should be investigated.
